The AERIFY program includes two additional ongoing trials: AERIFY-3, a Phase 2 mechanistic study assessing the impact of itepekimab on airway inflammation in patients with COPD, and AERIFY-4, a Phase ...

About itepekimab Itepekimab is a fully human monoclonal antibody that binds to and inhibits interleukin-33 (IL33), an initiator and amplifier of broad inflammation in COPD. IL33 is thought to be ...

Key Points Regeneron Pharmaceuticals is acquiring 23andMe for $256 million. Regeneron is going to keep the consumer genetics business. A big opportunity lies in using much of that data for research ...

This case involves an appeal from Regeneron Pharmaceuticals, Inc.’s (Regeneron) efforts to prevent defendants from marketing biosimilar versions ...

To help address the impact of COPD on patients and communities, global healthcare companies Sanofi and Regeneron are working together to study the ripple effects of COPD and to help create a ...

After a fourth quarter in which revenue boomed throughout the biopharma industry, there were reversals for several drugmakers ...

With a market cap of $63.5 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a fully integrated biotechnology company that ...

Bayer announces EMA committee recommends label extension approval for Eylea 8 mg: Berlin Monday, May 26, 2025, 17:00 Hrs [IST] Bayer announced that the Committee for Medicinal Pro ...

The Seoul Central District Court ruled against Regeneron, which had sought to block Samsung Bioepis from producing and selling a biosimilar referencing the US firm’s Eylea, a blockbuster medicine used ...

Regeneron (NASDAQ: REGN) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its previous ...

A recent U.S. Court of Appeals decision has implications not only for companies in health care, but for any organization ...